MarketPeel
Insider Trading Intelligence
DM

Duncan Mckechnie

VRTX
EVP, CHIEF COMMERCIAL OFFICER · VERTEX PHARMACEUTICALS INC / MA · CIK 0002062139
FILING MIX · LIFETIME25%/75%
BUYS
3
SELLS
9
TOTAL VALUE
$8.29M
COMPANIES
1
ACTIVE SINCE
Jan 2026
HOLDINGS NOW
11,001
AVG SELL PX
$488.74
TRADE KIND
SHOWING 12 / 12
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
4 backtested trades · 8 horizons · 12 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Duncan Mckechnie, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d4+75.00%-1.85%-1.45%-0.40%+0.09%
14d4+50.00%-2.31%-2.80%+0.49%+1.16%
30d4+100.00%-10.07%-5.21%-4.86%-2.87%
60d4+100.00%-11.32%+5.12%-16.44%-14.98%
90d4+100.00%-8.92%+9.30%-18.55%-18.55%
180d4(4 pending)
1y4(4 pending)
2y4(4 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
VRTX · 11,001 shares · as of Jul 2, 2026
06,12312,24518,36824,490SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2026
2026
2026
FLOW · 3 buys / 9 sellsCOVERAGE · 3 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
VRTX
VERTEX PHARMACEUTICALS INC / MA
SALE10b5-1
10b5-1 plan
1,541$519.00$799.8K11,001Jul 2, 2026Jul 7, 2026View →
VRTX
VERTEX PHARMACEUTICALS INC / MA
SALE10b5-1
10b5-1 plan
2,633$498.42$1.31M12,489Mar 11, 2026Mar 13, 2026View →
VRTX
VERTEX PHARMACEUTICALS INC / MA
SALE10b5-1
10b5-1 plan
2,437$475.30$1.16M15,122Mar 4, 2026Mar 6, 2026View →
VRTX
VERTEX PHARMACEUTICALS INC / MA
SALE10b5-1
10b5-1 plan
2,500$486.35$1.22M19,969Feb 25, 2026Feb 26, 2026View →
VRTX
VERTEX PHARMACEUTICALS INC / MA
SALE10b5-1
10b5-1 plan
2,410$489.00$1.18M17,559Feb 25, 2026Feb 26, 2026View →
VRTX
VERTEX PHARMACEUTICALS INC / MA
SALE
EVP, Chief Commercial Officer
873$485.11$423.5K22,469Feb 24, 2026Feb 26, 2026View →
VRTX
VERTEX PHARMACEUTICALS INC / MA
PURCHASEGRANT
Stock grant
4,96224,490Feb 17, 2026Feb 19, 2026View →
VRTX
VERTEX PHARMACEUTICALS INC / MA
SALE
EVP, Chief Commercial Officer
1,148$483.75$555.3K23,342Feb 17, 2026Feb 19, 2026View →
VRTX
VERTEX PHARMACEUTICALS INC / MA
SALE
EVP, Chief Commercial Officer
2,283$487.76$1.11M19,528Feb 13, 2026Feb 18, 2026View →
VRTX
VERTEX PHARMACEUTICALS INC / MA
SALE
EVP, Chief Commercial Officer
1,127$468.41$527.9K21,811Feb 10, 2026Feb 12, 2026View →
VRTX
VERTEX PHARMACEUTICALS INC / MA
PURCHASEGRANT
Stock grant
2,08022,938Jan 22, 2026Jan 26, 2026View →
VRTX
VERTEX PHARMACEUTICALS INC / MA
PURCHASEGRANT
Stock grant
4,72020,858Jan 22, 2026Jan 26, 2026View →
Other insiders · VRTX
Loading peer insiders…
About this filer
CIK 0002062139
ROLE
EVP, Chief Commercial Officer
PRIMARY
VRTX
COMPANIES
1
ACTIVE SINCE
Jan 2026
MARKETPEEL · /INSIDER/0002062139DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback